Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | ELANE | P08246 | 2/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 2/20 | 0.32 |
| ▸ | CA2 | P00918 | 2/20 | 0.32 |
| ▸ | CA4 | P22748 | 2/20 | 0.32 |
| ▸ | CES2 | O00748 | 2/20 | 0.32 |
| ▸ | CES1 | P23141 | 2/20 | 0.32 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.31 |
| ▸ | DRD2 | P14416 | 1/20 | 0.31 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.31 |
| ▸ | DRD1 | P21728 | 1/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.31 |
| ▸ | DRD3 | P35462 | 1/20 | 0.31 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
| ▸ | CASP3 | P42574 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12213944 | 0.89 | MAPT (0.42) | MAPTKDM4EALDH1A1HTTELANE | |
| SCHEMBL22381458 | 0.87 | ELANE (0.33) | MAPTKDM4EALDH1A1HTTELANE | |
| SCHEMBL23057573 | 0.85 | ELANE (0.36) | MAPTKDM4EALDH1A1HTTELANE | |
| SCHEMBL19105004 | 0.79 | ELANE (0.37) | MAPTKDM4EALDH1A1HTTELANE | |
| SCHEMBL26316856 | 0.77 | ELANE (0.34) | ELANE | |
| SCHEMBL19484370 | 0.76 | MAPT (0.41) | MAPTKDM4EALDH1A1HTTCA1 | |
| SCHEMBL27494904 | 0.75 | MAPT (0.40) | MAPTKDM4EALDH1A1HTTCA1 | |
| SCHEMBL27494903 | 0.75 | MAPT (0.40) | MAPTKDM4EALDH1A1HTTCA1 | |
| SCHEMBL12831907 | 0.75 | MAPT (0.40) | MAPTKDM4EALDH1A1HTTCA1 | |
| SCHEMBL11915792 | 0.73 | ELANE (0.42) | ELANEALOX15CA1CA2ADRB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10758636-B2 | Residualizing linkers and uses thereof | CENTRE FOR PROBE DEVELOPMENT AND COMMERCIALIZATION (CA) | 2020-09-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10758636-B2 | Residualizing linkers and uses thereof | CD44, CD47, MTCL3 | MAPT 1318/4885KDM4E 937/4885ALDH1A1 619/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.